SCHEMBL6077209

SCHEMBL6077209

COC(=O)C(O)=CC(=O)N(C)Cc1cccc2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.47
CYP2D6 P10635 2/20 0.47
CYP2C19 P33261 2/20 0.47
ATM Q13315 1/20 0.46
METAP2 P50579 4/20 0.46
TDP1 Q9NUW8 3/20 0.46
KMT2A Q03164 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
MEN1 O00255 2/20 0.42
NR1I2 O75469 1/20 0.42
DRD2 P14416 1/20 0.42
ADRA2C P18825 1/20 0.42
CNR1 P21554 1/20 0.42
SLC6A2 P23975 1/20 0.42
HTR2A P28223 1/20 0.42
SLC6A4 P31645 1/20 0.42
ADRA1A P35348 1/20 0.42
OPRK1 P41145 1/20 0.42
SLC6A3 Q01959 1/20 0.42
KCNH2 Q12809 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6078426 0.86 ATM (0.42) CYP1A2CYP2D6CYP2C19ATMMETAP2
SCHEMBL6414135 0.83 KMT2A (0.36) ATMKMT2AMEN1SLC6A4SLC6A3
SCHEMBL6414133 0.83 KMT2A (0.36) ATMKMT2AMEN1SLC6A4SLC6A3
SCHEMBL6421217 0.82 TSHR (0.39) CYP1A2CYP2D6CYP2C19KMT2AMEN1
SCHEMBL6413772 0.82 MEN1 (0.43) KMT2AMEN1ALDH1A1
SCHEMBL6413774 0.82 MEN1 (0.43) KMT2AMEN1ALDH1A1
SCHEMBL6421220 0.82 TSHR (0.39) CYP1A2CYP2D6CYP2C19KMT2AMEN1
SCHEMBL6413264 0.82 MEN1 (0.50) ATMTDP1KMT2AL3MBTL1MEN1
SCHEMBL6413268 0.82 MEN1 (0.50) ATMTDP1KMT2AL3MBTL1MEN1
SCHEMBL6417762 0.81 SLC6A2 (0.43) CYP2D6TDP1KMT2AMEN1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109186-B2 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment BRISTOL-MYERS SQUIBB COMPANY (US) 2006-09-19 US disclosed
US-20040110804-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-06-10 US disclosed
WO-2004004657-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110804-A1 HIV integrase inhibitors CDKN1A, SAMHD1, CTCF CYP1A2 483/4885CYP2D6 1226/4885CYP2C19 806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.